HYPERTENSION AS A PREDICTIVE FACTOR OF EFFECT OF BEVACIZUMAB IN TREATMENT OF BREAST CANCER
- At: 2015 FIP Congress in Düsseldorf (Germany)
- Type: Poster
- By: TANAKA, Hiroaki (Kagawa University Hospital, Pharmacy, Miki, Japan)
- Co-author(s): Hiroaki Tanaka
Bevacizumab (Bev), an inhibitor of vascular endothelial growth factor (VEGF), is used in combination with paclitaxel (Pac) for the treatment of inoperable, advanced, or recurrent breast cancer (Pac on days 1, 8, and 15, Bev on days 1 and 15, of a 28 day cycle). Hypertension is a known side effect associated with Bev, with its incidence being 17.9% .. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.